Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

CAPN12 Gene Expression as a Molecular Discriminator

12. november 2026 oppdatert av: Sherine Adly Hashem, South Valley University

CAPN12 Gene Expression as a Molecular Discriminator Between Methotrexate Treated Chronic Plaque Psoriasis and Psoriatic Arthritis

Psoriasis is a chronic immune-mediated inflammatory disease with systemic manifestations. Psoriatic arthritis is an important extracutaneous manifestation that can lead to progressive joint damage and functional disability if not recognized early.

Methotrexate remains a commonly used systemic therapy in both chronic plaque psoriasis and psoriatic arthritis, mainly through anti-inflammatory and immunomodulatory effects.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Psoriasis is a chronic immune-mediated inflammatory disease with systemic manifestations. Psoriatic arthritis is an important extracutaneous manifestation that can lead to progressive joint damage and functional disability if not recognized early.

Methotrexate remains a commonly used systemic therapy in both chronic plaque psoriasis and psoriatic arthritis, mainly through anti-inflammatory and immunomodulatory effects.

CAPN12 is a calcium-dependent cysteine protease expressed in the epidermis and hair follicles and implicated in skin barrier biology and keratinocyte differentiation. Recent integrative single-cell RNA sequencing and Mendelian randomization work identified CAPN12 among genetically informed psoriasis related candidate genes and linked it to increased psoriasis susceptibility.

The same work reported that these candidate genes were predominantly expressed in CD4+ T cells, supporting the feasibility of peripheral blood mononuclear cell-based expression assessment .

Because methotrexate can modulate immune-cell activity, this study will restrict patient recruitment to methotrexate-treated patients on a stable regimen. This design aims to explore whether CAPN12 expression can discriminate between methotrexate-treated cutaneous-only psoriasis and methotrexate-treated psoriatic arthritis, and whether CAPN12 expression correlates with clinical activity indices.

Studietype

Observasjonsmessig

Registrering (Antatt)

105

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Qina, Egypt
        • Rekruttering
        • South Valley University Hospital
        • Ta kontakt med:
        • Ta kontakt med:
        • Underetterforsker:
          • Shimaa Saber Ahmed, M.D

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 70 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

  • Type of the study: Case-control molecular study.
  • Study Setting: Qena University Hospital, Department of Dermatology, Venereology& Andrology and Rheumatology Clinics.
  • Study subjects: This study will include adult participants recruited from the outpatient Dermatology and Rheumatology Clinics.
  • Receiver operating characteristic curve analysis will be used to evaluate the diagnostic performance of CAPN12 expression.
  • Multivariate logistic regression may be performed to test whether CAPN12 expression is independently associated with psoriatic arthritis status.

Beskrivelse

Inclusion Criteria:

  • Patients aged 18 -70 years.
  • The severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI > 12 (severe severity).
  • Confirmed diagnosis: Psoriasis vulgaris (PsV) or Psoriatic arthritis (PsA) diagnosed by a dermatologist/rheumatologist.
  • Willingness to participate: Signed informed consent.
  • Patients on stable dose of methotrexate (MTX) therapy.
  • Availability for follow-up: Patients must be willing and able to attend scheduled visit.

Exclusion Criteria:

  • Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus).
  • Pregnancy and lactation.
  • Patients currently undergoing immunosuppressive or systemic therapies.
  • Patients with known genetic disorders affect immune system function.
  • Patients with liver or kidney impairment.
  • Patients with allergy or contraindication to methotrexate.
  • Patients with active or uncontrolled infections, including chronic infections like tuberculosis.
  • Previous genetic analysis: Patients who have previously undergone genetic analysis for the CAPN12 gene expression.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: CASE_CONTROL
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Chronic plaque psoriasis group

About 35 patients suffering from chronic plaque psoriasis and clinically diagnosed chronic plaque psoriasis receiving a stable methotrexate regimen for at least 12 weeks, with no clinical evidence of psoriatic arthritis.The recommended starting dose for a patient with no risk factors is 10 to 20 mg/wk, the therapeutic dose for most patients is 15 mg/wk, and the maximum dose is between 20 - 25 mg/wk.

to evaluate CAPN12 gene expression as a potential molecular discriminator between methotrexate-treated chronic plaque psoriasis patients and methotrexate treated psoriatic arthritis patients.

Andre navn:
  • CAPN12 gene expression
Psoriatic arthritis group

About 35 patients suffering from Psoriatic arthritis and diagnosed with psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis (CASPAR) and receiving a stable methotrexate regimen for at least 12 weeks.The recommended starting dose for a patient with no risk factors is 10 to 20 mg/wk, the therapeutic dose for most patients is 15 mg/wk, and the maximum dose is between 20 - 25 mg/wk.

to evaluate CAPN12 gene expression as a potential molecular discriminator between methotrexate-treated chronic plaque psoriasis patients and methotrexate treated psoriatic arthritis patients.

Andre navn:
  • CAPN12 gene expression
Healthy Control group

About 35 participants inwhich age- and sex-matched apparently healthy individuals with no history of psoriasis, psoriatic arthritis, other autoimmune or chronic inflammatory diseases, and no history of methotrexate therapy.

to evaluate CAPN12 gene expression as a potential molecular discriminator between methotrexate-treated chronic plaque psoriasis patients and methotrexate treated psoriatic arthritis patients.

Andre navn:
  • CAPN12 gene expression

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
CAPN12 mRNA expression
Tidsramme: 3 Months

Assessment of the Difference in relative CAPN12 mRNA expression among the three studied groups.

3 Months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pain Relief
Tidsramme: 3 Months

Assessment of the patients of the study from the pain after treatment using Visual Analogue Scale (VAS) where as 0 for none up to 10 for very severe

3 Months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studiestol: Eisa Mohammed Hegazy, M.D, Professor of Dermatology,Venereology and Andrology,Faculty of Medicine
  • Studieleder: Marwa Alyan Abdelaziz Mohammed, M.D, Lecturer of Dermatology,Venereology and Andrology,Faculty of Medicine

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. oktober 2026

Primær fullføring (Antatt)

1. oktober 2027

Studiet fullført (Antatt)

10. oktober 2027

Datoer for studieregistrering

Først innsendt

12. november 2026

Først innsendt som oppfylte QC-kriteriene

12. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • CAPN12 Gene Expression

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .